HOME >> BIOLOGY >> NEWS
Vion Demonstrates Readiness Of First Tumor-Targeting Salmonella For Human Testing Against Solid Tumors

Stability, Safety and Efficacy Demonstrated for Novel Bacterial Anticancer Agent

NEW HAVEN, CT (April 12, 1999): Research by scientists at Vion Pharmaceuticals (Nasdaq: VION) and their Yale University collaborators demonstrates the suitability of the company's lead TAPETR vector, VNP20009, to enter human clinical testing. At the annual meeting of the American Association of Cancer Research (AACR) Vion scientists presented data demonstrating the genetically engineered Salmonella bacteria's overall safety profile and tumor targeting ability, including TAPET's safety when administered to non-human primates. In addition, they reported the ability of unarmed TAPET organisms (without "warheads") to inhibit both primary and metastatic tumors by more than 90% and to prolong survival in mouse xenograft models (human tumor tissue transplanted into mice) of several human cancers. In March, Vion announced that the company had filed an Investigational New Drug (IND) application to begin human safety testing with TAPET in the United States later this year. The U.S. filing is in addition to regulatory filings made by Vion in support of clinical trials of TAPET in Europe. Vion is developing TAPET organisms as vectors for the targeted, systemic delivery of anticancer agents to tumors throughout the body.

David Bermudes, Ph.D., associate director of biology at Vion, said, "VNP20009 possesses all of the properties required for its safe use in humans. These include attenuated virulence, a reduction in the potential of the bacterium to elicit septic shock, genetic stability in its safety-related mutations, and sensitivity to conventional antibiotics. At the same time, VNP20009 maintains TAPET's desirable anti-tumor properties, including the ability to selectively amplify in tumors at levels of at least 500:1 compared with normal tissues and to suppress tumor growth by more than 90%. Moreover, the VNP20009 TAPET strain is easily amenable
'"/>

Contact: Joan Kureczka
jkureczka@aol.com
415-821-2413
Kureczka/Martin Associates
11-Apr-1999


Page: 1 2 3

Related biology news :

1. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
2. Engineering Animation, Inc. Demonstrates Internet Anatomy At Visible Human Project Conference
3. Study Demonstrates High Conservation Potential Of Logged Rainforest
4. First glimpse of DNA binding to viral enzyme
5. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
6. 2nd media alert First Scientific Conference on Childhood Leukaemia
7. First International Scientific Conference on Childhood Leukaemia
8. First ever standards linking climate change, biodiversity and poverty seek global peer review
9. First genetic comparison of purebred domestic dogs produces surprises
10. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
11. First target for childhood malaria vaccine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... the prestigious international IAIR Award for the most innovative high security ePassport ... ... Maldives Immigration Controller General, Mr. ... on the right) have received the IAIR award for the "Most innovative ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... 10, 2017 , ... USDM Life Sciences , the ... sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer Jaye ... GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to achieving ...
Breaking Biology Technology:
Cached News: